New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ From The Last 14 Days
Check below for free stories on CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
July 28, 2014
15:47 EDTAETNotable companies reporting before tomorrow's open
Subscribe for More Information
14:58 EDTAETEarnings Preview: Aetna shares up 16% since last earnings report
Subscribe for More Information
12:46 EDTMDTMedtronic receives FDA approval for PRESTIGE cervical disc system
Subscribe for More Information
11:07 EDTSTJ, MDT, BSXLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist Arie Pieter Kappetein, MD, PhD and Bernhard Meier, MD, assess EU cardiology trends on an Analyst/Industry conference call to be held on July 31 at 3 pm.
10:36 EDTAETAetna and Geisinger Health System reach five-year agreement
Subscribe for More Information
10:02 EDTWCGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:17 EDTWCGOn The Fly: Pre-market Movers
Subscribe for More Information
08:17 EDTHUM, WCG, MOH, CNCMCO sell-off provides buying opportunity, says Leerink
Subscribe for More Information
07:51 EDTWLPWellPoint price target raised to $130 from $112 at Cowen
Subscribe for More Information
07:12 EDTWCGWellCare upgraded to Buy from Neutral at Goldman
Subscribe for More Information
06:53 EDTWCGWellCare upgraded to Neutral from Underperform at Sterne Agee
Subscribe for More Information
06:52 EDTMDTFormer official says Obama could limit inversion deals, NY Times reports
President Obama could limit tax inversion deals on his own authority, said Stephen Shay, former deputy assistant Treasury secretary for international tax affairs in the Obama administration, according to The New York Times. A 1969 law gives the president the ability to restrict inversion deals, said Shay, who also worked in the Reagan administration, the newspaper stated. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Alletgan (AGN). Reference Link
06:32 EDTBSXJ&J dispute with Boston Scientific looks set to go to trial, NY Times says
Subscribe for More Information
July 25, 2014
16:18 EDTWCGOn The Fly: Closing Wrap
Subscribe for More Information
12:51 EDTWCGOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday and on track to end a week marked by a torrent of earnings reports on a definite down note. Some high-profile disappointments weighed on the major averages, as Visa (V) and Amazon.com (AMZN) both fell significantly after their quarterly reports last night, dragging on the Dow and Nasdaq, respectively. The domestic economic calendarís sole release of consequence, the durable goods orders report, came out before the open and was better than expected, but that did little to brighten the market's negative tone. ECONOMIC EVENTS: In the U.S., durable goods orders rebounded 0.7% in June after a 1.0% decline in the prior month, beating expectations for June increase of 0.5%. COMPANY NEWS: Shares of Amazon.com fell 10% after the e-commerce giant reported in-line second quarter revenue but a much higher than expected loss. A number of analysts responded to the news by downgrading the stock, while several others cut their price targets on the shares... Visa reported Q3 earnings per share and revenue that topped consensus forecasts, but its fiscal year EPS growth outlook was trimmed its fiscal year revenue growth view to be in the 9-10% range from its prior forecast for low double-digit constant revenue growth in the 10-11% range. Shares of the Dow Jones Industrial Average component slid 4% following the report and guidance. MAJOR MOVERS: Among the notable gainers following their earnings reports were Datalink (DTLK), which jumped 17%, Mellanox (MLNX), which rose 13%, and VeriSign (VRSN), which gained 11%. Among the noteworthy losers was WellCare (WCG), which plunged 20% after the managed care company pre-announced significantly weaker than expected results. Also lower following their earnings reports were Swift Transport (SWFT), which fell nearly 15%, and Pandora (P), which dropped about 13%. INDEXES: Near midday, the Dow was down 131.61, or 0.77%, to 16,952.19, the Nasdaq was down 24.45, or 0.55%, to 4,447.66, and the S&P 500 was down 9.04, or 0.45%, to 1,978.94.
12:11 EDTCI, AET, UNH, WLP, WCGWellCare profit warning sinks managed care names
A number of managed care names are falling after one of the companies in the sector, WellCare (WCG), preannounced significantly weaker than expected results. UBS, however, recommends using the weakness in the sector as a buying opportunity. WHAT'S NEW: WellCare, which specializes in managing Medicaid and Medicare plans, preannounced a second quarter per share loss of 7c, excluding certain items. Analysts on average expected the company to report a per share profit of 90c. The company's revenue came in slightly above expectations. WellCare cut its full-year earnings per share guidance to $2.20-$2.50 from $4.40-$4.75. The company said recipients of a new Medicaid program in Florida utilized more medical services than expected since the company began administering the program in May. Additionally, the company took an impairment charge related to an acquisition and it had an unfavorable reserve development. ANALYST REACTION: The factors cited by WellCare for the cut in its guidance appear to be specific to that company, UBS analyst A.J. Rice wrote. Meanwhile, data from other companies that administer Medicaid plans indicate that the increased utilization costs in that state are also specific to WellCare, Rice contended. For example, Centene (CNC) reported Q2 results earlier this week and indicated that utilization trends for newly covered beneficiaries in Florida was largely in line with expectations, while UnitedHealth (UNH) said its Medicaid business had performed well last quarter, the analyst stated. Additionally, WellCare said that its higher than expected medical utilization costs had been caused primarily by drug costs that exceeded its forecast, Rice stated. Since drug costs tend to be known relatively quickly, United Health and Centene would have divulged any issues with drug costs in conjunction with their Q2 results, Rice said. The analyst recommended that investors buy Aetna (AET), Cigna (CI), United Health and WellPoint (WLP) on any weakness today. PRICE ACTION: In late morning trading, Aetna fell 1.5% to $83, Cigna lost 1% to $95.50, UnitedHealth lost 1% to $84.50, WellPoint slid 1.5% to $113.50 and Centene tumbled 7% to $74 while WellCare plunged 19% to $62.
10:52 EDTCI, AET, HUM, WLP, CNC, WCGWellCare issues largely company-specific, says UBS
UBS notes that aside from WellCare (WCG), which attributed its lowered guidance to the start-up of its Florida MMA program and other issues, that Centene (CNC), WellPoint (WLP), UnitedHealth (UNH) and Humana (HUM) are the leaders in Medicaid in the state. However, the firm believes a majority of WellCare's issues appear company specific and UBS views any weakness in UnitedHealth, WellPoint, Aetna (AET), or Cigna (CI) as opportunity to buy those four stocks, on all of which it has Buy ratings.
10:02 EDTWCG, CNCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:25 EDTWCGOn The Fly: Pre-market Movers
Subscribe for More Information
07:24 EDTWCGWellCare downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded WellCare to Market Perform citing less confidence in management and weaker than expected performance in the new Florida Medicaid business following the company's Q2 results. Wells lowered its price target range for shares to $54-$58 from $83-$89.
07:22 EDTWCG, CNCCentene downgraded to Market Perform from Outperform at Wells Fargo
Subscribe for More Information
07:00 EDTWCGWellCare downgraded to Market Perform from Outperform at Raymond James
Subscribe for More Information
06:40 EDTWCGWellCare downgraded to Market Perform from Outperform at Wells Fargo
Subscribe for More Information
06:40 EDTCNCCentene downgraded to Market Perform from Outperform at Wells Fargo
Subscribe for More Information
06:30 EDTMDTObama calls on Congress to end inversion deals, NY Times reports
Subscribe for More Information
July 24, 2014
18:15 EDTWCGWellCare down 20% after Q2 earnings and lowering FY14 guidance
Subscribe for More Information
18:13 EDTWCGWellCare lowers FY14 EPS guidance to $2.20-$2.50 from $4.40-$4.75
Subscribe for More Information
18:09 EDTWCGWellCare reports Q2 adjusted EPS (7c), may not compare to consensus 90c
Subscribe for More Information
10:56 EDTBSXStocks with call strike movement; NRG BSX
NRG Energy (NRG) January 35 call option implied volatility decreased 2% to 24, NRG Energy Boston Scientific (BSX) January 15 call option implied volatility decreased 2% to 25 according to IVolatility.
10:03 EDTHNTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:51 EDTHNTHealth Net upgraded at BofA/Merrill
Subscribe for More Information
08:28 EDTBSXBoston Scientific sees FY operating margin approaching 20%
Subscribe for More Information
08:19 EDTMDTLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
07:04 EDTBSXBoston Scientific raises FY14 adjusted EPS to 79c-83c from 77c-82c
Subscribe for More Information
07:02 EDTBSXBoston Scientific sees Q3 adjusted EPS 18c-20c, consensus 19c
Subscribe for More Information
07:02 EDTBSXBoston Scientific reports Q2 Rhythm Management revenue growth of 7%
Subscribe for More Information
07:01 EDTBSXBoston Scientific reports Q2 adjusted EPS 21c, consensus 19c
Reports Q2 revenue $1.87B, consensus $1.87B
06:50 EDTWCG, UNH, HUM, MOH, CNC, CI, WLP, AGP, HNT, AET, HSConsumers received $9B in refunds from health insurers, The Hill says
Subscribe for More Information
06:37 EDTHNTHealth Net upgraded to Buy from Underperform at BofA/Merrill
Subscribe for More Information
July 23, 2014
17:10 EDTBSXBoston Scientific receives CE Mark for Agent Drug Coated Balloon
Subscribe for More Information
15:30 EDTBSXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
07:45 EDTSTJSt. Jude Medical management to meet with Deutsche Bank
Subscribe for More Information
July 22, 2014
13:46 EDTWCG, UNH, WLP, AET, MOH, HS, HNT, CNC, CI, AGP, HUMCourt upholds Obamacare subsidies, NY Times says
Subscribe for More Information
10:43 EDTWCG, UNH, WLP, AET, CNC, HS, MOH, AGP, HNT, CI, HUMAppeals court bars subsidies in health care law
A three-judge panel of the D.C. Circuit Court of Appeals struck down part of President Obama's healthcare law by siding today with plaintiffs who argued that the law barred the government from giving subsidies to people in states that chose not to set up their own insurance marketplaces. The appeals court stated, "Because we conclude that the ACA unambiguously restricts the section 36B subsidy to insurance purchased on Exchanges 'established by the State,' we reverse the district court and vacate the IRSís regulation." Twenty-seven states decided against setting up marketplaces, and another nine states partially opted out, according to the Washington Post.
08:25 EDTBSXBoston Scientific risk/reward favorable into Q2 results, says RBC Capital
Subscribe for More Information
08:02 EDTSTJSt. Jude announces FlexAbility Ablation Catheter CE Mark approval, first use
St. Jude Medical CE Mark approval and first use of the FlexAbility Ablation Catheter. Designed with feedback from physician thought-leaders around the world, the FlexAbility catheter combines a unique, irrigated flexible catheter tip with a state-of-the-art handle and catheter design. The next-generation flexible tip technology was designed to reduce complications associated with ablation procedures through its ability to bend and conform to the cardiac anatomy, decreasing the amount of pressure distributed to a patientís heart wall while simultaneously increasing the stability of therapy delivery.
06:47 EDTCNCCentene up 2.1% following Q2 earnings release
Subscribe for More Information
06:14 EDTCNCCentene sees FY14 EPS $3.70-$3.90, consensus $3.73
Subscribe for More Information
06:12 EDTCNCCentene reports Q2 EPS ex-items 95c, consensus 72c
Reports Q2 revenue $4.02B, consensus $3.66B. Reports Q2 EPS 79c. Reports Q2 premium and service revenues $3.74B.
July 21, 2014
16:38 EDTBSXBoston Scientific receives FDA approval for REBEL Platinum Stent system
Subscribe for More Information
11:02 EDTUNHUnitedHealth, Banner Health Network announce collaboration
Subscribe for More Information
08:16 EDTMDTDeutsche Bank analysts hold an analyst/industry conference call
Subscribe for More Information
July 18, 2014
16:47 EDTUNHMarket ends week higher as earnings, M&A offset geopolitical tensions
Subscribe for More Information
12:51 EDTMDTKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
08:45 EDTUNHUnitedHealth price target raised to $94 from $84 at Oppenheimer
Subscribe for More Information
July 17, 2014
16:52 EDTUNHOn The Fly: Closing Wrap
Subscribe for More Information
13:18 EDTUNHOn The Fly: Midday Wrap
Subscribe for More Information
09:13 EDTUNHUnitedHealth expects improving environment in 2016 and beyond
Expects to expand up to two dozen state exchanges in 2014. Project 6% commercial medical cost trend for 2016, with costs in line with company's plan and remains moderate. Expects margins to reach 7% this year, in line with original forecast. Expects Optum revenue to accelerate in 2H14, and particularly in Q4. Comments taken from Q2 earnings conference call.
06:18 EDTUNHUnitedHealth reports Q2 Optum revenue $11.7B
Subscribe for More Information
06:18 EDTUNHUnitedHealth raises low end of FY14 EPS to $5.50-$5.60 from $5.40-$5.60
Subscribe for More Information
06:18 EDTUNHUnitedHealth reports Q2 EPS $1.42, consensus $1.26
Reports Q2 revenue $32.57B, consensus $32B
July 16, 2014
15:27 EDTUNHNotable companies reporting before tomorrow's open
Subscribe for More Information
14:32 EDTUNHUnitedHealth July 84 straddle priced for 2.8% move into Q2
10:36 EDTMDTTreasury calls on Congress to halt inversion deals
Subscribe for More Information
08:32 EDTSTJSt. Jude Medical sees revenue growth rate accelerating in 2H
Subscribe for More Information
08:18 EDTSTJ St. Jude Medical sees total Q3 CRM sales $660M-$690M
Sees total FY14 CRM sales $2.81B-$2.85B. Sees Q3 AF product sales $240M-$260M, FY14 AF product sales $1.3B-$1.6B. Sees Q3 cardiovascular product sales $315M-$335M, FY14 cardiovacular product sales $1.36B-$1.39B. Sees Q3 neuromodulation product sales $100M-$110M, sees FY14 neuromodulation product sales $440M-$460M. Sees $15M-$20M related to CardioMEMS product line. Says assumes R&D tax credit will be extended for 2014. Says expects to add $10M-$15M in sales related to NeuroTherm product line in 2014, sees acquisition neutral to EPS in 2014. Sees FY14 gross profit margin 71.5%-72%. Still sees FY14 SG&A as a percentage of net sales to be 33.5%-34%. Sees FY14 effective tax rate 18%-18.5%. Comments made on the Q2 earnings conference call.
07:59 EDTMDTTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical raises FY14 adjusted EPS view to $3.96-$4.01 from $3.95-$4.00
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees Q3 adjusted EPS 95c-97c, consensus 96c
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees FY14 adjusted EPS $3.96-$4.01, consensus $3.99
Sees FY14 revenue $5.64B-$5.76B, consensus $5.7B.
07:31 EDTSTJSt. Jude Medical reports Q2 adjusted EPS $1.02, consensus $1.00
Reports Q2 revenue $1.45B, consensus $1.44B.
07:18 EDTMDTScoliosis Research Society to hold annual meeting
Subscribe for More Information
July 15, 2014
15:19 EDTSTJNotable companies reporting before tomorrow's open
Subscribe for More Information
11:41 EDTSTJSt. Jude Medical technical comments ahead of earnings
Subscribe for More Information
08:00 EDTSTJSt. Jude Medical management to meet with Leerink
Meeting to be held in New York on July 22 hosted by Leerink.
July 14, 2014
19:19 EDTBSXBoston Scientific receives CE Mark for 25 mm Lotus Valve System
Subscribe for More Information
16:15 EDTHUMHumana, Tenet sign new multi-year national agreement
Subscribe for More Information
09:28 EDTCNCCentene best positioned Medicaid pure play to post Q2 EPS beat, says Sterne Agee
Subscribe for More Information
09:23 EDTWLPWellPoint Q2 EPS likely to beat consensus by 55c, says Sterne Agee
Subscribe for More Information
09:05 EDTSTJSt. Jude Medical to acquire NeuroTerm for approximately $200M in cash
St. Jude Medical has signed a definitive agreement to acquire privately held NeuroTherm, a manufacturer of interventional pain management therapies, for approximately $200M in cash. NeuroTherm is involved in the treatment of spinal pain using radiofrequency ablation, a segment of the chronic pain market in which St. Jude Medical does not currently participate. The company expects to complete this transaction by the end of the third quarter, subject to customary closing conditions. NeuroTherm is expected to add approximately $10M-$15M to St. Jude Medicalís 2014 sales. Excluding acquisition-related expenses, this transaction will be neutral to St. Jude Medicalís consolidated EPS in 2014 and accretive thereafter on a GAAP basis.
09:02 EDTBSXBoston Scientific receives CE mark for Ranger drug-coated balloon
Boston Scientific has received CE Mark for the Ranger Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Balloon provides physicians with an additional option to treat peripheral artery disease, delivering an anti-stenotic drug to diseased vascular tissue while leaving no permanent implant behind.
07:22 EDTWLP, HUM, MOHHealthcare Education Associates to hold a conference
4th Annual RISE California Summit to be held in San Diego on July 13-15.
07:12 EDTMDTCovidien downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use